John Theurer Cancer Center

What John Theurer Cancer Center does

John Theurer Cancer Center (JTCC) is an NCI-Designated comprehensive cancer center operating within Hackensack University Medical Center as the oncology flagship of the Hackensack Meridian Health network in New Jersey. The center provides specialized cancer diagnosis, treatment, and survivorship services across all major cancer types, with particular concentration in hematologic malignancies and blood cancers. It serves a broad base of individual oncology patients and referring physicians, supported by a clinical network of more than 1,200 doctors, nurses, researchers, and clinicians, plus an affiliated Hennessy Institute for Cancer Prevention & Applied Molecular Medicine.

The center's core capabilities span advanced cell therapy programs (including CAR-T), stem cell transplantation, next-generation Tyrosine Kinase Inhibitor (TKI) treatments, biologically-guided radiation therapy (BgRT), AI-powered diagnostics, and a novel liquid biopsy technique combining cell-free RNA and DNA analysis. More than 350 ongoing clinical trials, with particular depth in Phase I studies, position JTCC as an active clinical research site that translates laboratory findings into patient care. The 2024 American Society of Hematology Annual Meeting featured 65 research studies from JTCC covering cell therapy, targeted agents, AI diagnostics, and stem cell transplantation.

JTCC generates revenue through two primary streams: patient care services billed through insurance, Medicare, Medicaid, and self-pay arrangements, and clinical trial revenue and grants from pharmaceutical, biotech, government, and foundation sponsors. Demand is generated through physician referrals, the dedicated 1-833-CANCER-MD contact line, online provider search, the MyChart/HMH Well digital platform, and emergency pathways. As a nonprofit, tax-exempt 501(c)(3) division of Hackensack Meridian Health, the center reinvests operating performance into research, clinical programs, and community cancer care delivery across the New Jersey network.

Name

John Theurer Cancer Center

Legal name

Hackensack Meridian Health, Inc.

Website

https://jtcancercenter.org

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

John Theurer Cancer Center is an NCI-Designated comprehensive cancer center within Hackensack Meridian Health in New Jersey, delivering specialized oncology and hematology care, cell therapy, stem cell transplantation, and 350+ clinical trials through a network of 1,200+ clinicians.

Ownership category

akta.pro rank

Product category

Oncology and Cancer Care Services

NAICS

Offices of Physicians (62111), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Cancer treatment services
• Oncology clinical trials
• Hematology care
• Precision oncology
• Cancer research programs

Headquarters

HQ city

Hackensack

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Revenue generated through direct patient care services including diagnostics, treatments, surgeries, and clinical consultations. Billed through insurance plans, Medicare, Medicaid, and self-pay arrangements typical of healthcare provider organizations.
2. Clinical Trial Revenue: Revenue and funding support from conducting sponsored clinical trials for pharmaceutical and biotech partners, as well as government and foundation grants supporting research programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

John Theurer Cancer Center is an NCI-Designated comprehensive cancer center that delivers specialized oncology diagnosis, treatment, and survivorship care through a network of more than 1,200 clinicians at Hackensack University Medical Center. It runs more than 350 ongoing clinical trials, including Phase I studies, and offers advanced therapies such as cell therapy, TKI treatments, stem cell transplantation, biologically-guided radiation therapy (BgRT), and AI-assisted diagnostics, complemented by cancer prevention services through the Hennessy Institute.

Product overview

John Theurer Cancer Center is an NCI-designated comprehensive cancer center offering a unified portfolio of specialized cancer care services. The center provides highly specialized, innovative cancer care through a network of over 1,200 professionals, combining Cancer Care Services, Cancer Research and Clinical Trials (350+ trials), Cancer Support Services, and the Hennessy Institute for Cancer Prevention. Specialized treatments include TKI treatments, BgRT therapy, cell therapy, and stem cell transplantation, with advanced diagnostics including liquid biopsy techniques and AI-powered diagnostics. The center integrates these components to deliver personalized treatment plans based on patient genetic makeup, individual needs and personal goals.

Differentiator

Problem solved

Functional benefit

Brands

• Hennessy Institute for Cancer Prevention & Applied Molecular Medicine: Institute focused on cancer prevention and applied molecular medicine, part of John Theurer Cancer Center.

Products and services

• Cancer Care Services Comprehensive cancer care services covering diagnosis, treatment, and after-care support across multiple cancer types, delivered to oncology patients in New Jersey by John Theurer Cancer Center specialists.
• Cancer Research and Clinical Trials Program
• Hennessy Institute for Cancer Prevention & Applied Molecular Medicine
• Cancer Support Services
• Tyrosine Kinase Inhibitor (TKI) Treatments
• BgRT (Biologically-guided Radiation Therapy)
• Cell Therapy Research Program
• Stem Cell Transplantation
• Liquid Biopsy Technique

Quantifiable outcome

• 65 research studies presented at the 67th American Society of Hematology Annual Meeting
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

One partnership is on record.

• Hackensack Meridian HealthcoreStrategic or Co-development PartnerJohn Theurer Cancer Center is an integral part of the Hackensack Meridian Health network, operating within the Hackensack University Medical Center. The center benefits from the broader network infrastructure of 1,200+ clinicians, shared technology platforms, and multi-facility coordination across New Jersey.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• City of Hope Comprehensive Cancer Center: NCI-Designated Comprehensive Cancer Center in California with major CAR-T/cell therapy program, stem cell transplantation leadership, and extensive clinical trial pipeline. Closely comparable to JTCC on blood-cancer specialization, cell therapy focus, and translational research orientation.
• Fred Hutchinson Cancer Center: NCI-Designated Comprehensive Cancer Center formerly affiliated with UW Medicine, widely known for pioneering stem cell transplantation, immunotherapy, and CAR-T research. Comparable to JTCC on blood-cancer and cell-therapy leadership, with larger research footprint.
• Abramson Cancer Center (Penn Medicine): NCI-Designated Comprehensive Cancer Center at the University of Pennsylvania, a global leader in CAR-T cell therapy development (e.g., collaboration with Novartis on Kymriah). Comparable to JTCC on cell therapy leadership and academic cancer-research activity.
• Moffitt Cancer Center: NCI-Designated Comprehensive Cancer Center in Tampa with strong hematologic malignancies program and translational research portfolio. Comparable to JTCC as a specialized regional cancer center with both clinical and trial-driven business model.
• Roswell Park Comprehensive Cancer Center: NCI-Designated Comprehensive Cancer Center in Buffalo, NY with strong hematologic malignancies program, cell therapy, and clinical research output. Comparable to JTCC as a regionally-anchored NCI-designated center with similar mix of patient care, research, and Phase I trial activity.
• Winship Cancer Institute of Emory University: Emory-affiliated NCI-Designated Comprehensive Cancer Center offering cell therapy, hematology programs, and broad clinical trials portfolio in the Southeast. Comparable to JTCC as an academic-affiliated NCI cancer center with similar research/treatment mix.
• Perlmutter Cancer Center (NYU Langone): NCI-Designated Comprehensive Cancer Center at NYU Langone Health with major hematologic malignancies and cell therapy programs serving the greater New York/New Jersey metro. Directly comparable to JTCC on geography, oncology service mix, and academic credentials.

Broad incumbents

• Dana-Farber Cancer Institute: Harvard-affiliated NCI-Designated Comprehensive Cancer Center with leading hematologic malignancies program, large Phase I/II trial portfolio, and prominent ASH Annual Meeting output. Comparable to JTCC on academic research presence and blood-cancer focus, with larger national brand.
• Memorial Sloan Kettering Cancer Center: National NCI-Designated Comprehensive Cancer Center based in New York with deep clinical trial portfolio, CAR-T/cell therapy programs, and hematology/oncology specialization. Closest direct analog to JTCC in scope of services, although larger and operating at national rather than regional scale.
• MD Anderson Cancer Center: University of Texas NCI-Designated Comprehensive Cancer Center and the largest cancer center in the U.S., offering cell therapy, stem cell transplantation, AI diagnostics, and 1,000+ active trials. Comparable to JTCC in multidimensional oncology platform, though operates at significantly larger scale and broader geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jtcancercenter
• Facebookfacebook.com/jtcancercenter
• LinkedInlinkedin.com/company/john-theurer-cancer-center

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about John Theurer Cancer Center